Status:

RECRUITING

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Lead Sponsor:

TheraOp

Collaborating Sponsors:

AstraZeneca

Conditions:

Stage III Non-small Cell Lung Cancer

Locally Advanced

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Multinational, randomized, controlled, open-label, multicenter phase II trial. Eligible patients will be randomized in a ratio of 1:1 to Experimental Arm (FDG-PET-based small volume accelerated radiot...

Eligibility Criteria

No eligibility criteria provided.

Key Trial Info

Start Date :

July 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2028

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT06102057

Start Date

July 1 2024

End Date

June 1 2028

Last Update

December 17 2025

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

Universitätsklinik Carl Gustav Carus der Technischen Universität Dresden

Dresden, Germany, 01307

2

Universitätsklinikum Essen - Klinik für Strahlentherapie

Essen, Germany, 45122

3

Medical Center - University Of Freiburg, Department of Radiation Oncology

Freiburg im Breisgau, Germany, 79106

4

Universitätsmedizin Göttingen, Department for Radiotherapy and Radiooncology

Göttingen, Germany, 37075

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC | DecenTrialz